ClinicalTrials.gg
CompletedNCT04742361Updated Jul 15, 2025

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

A Phase 3 interventional study of [18F]PSMA-1007 in Prostate Cancer and Prostate Cancer Recurrent, sponsored by ABX advanced biochemical compounds GmbH. Completed at 6 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by ABX advanced biochemical compounds GmbH · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
721st of 3,024
136 · median 48
Started
2021
with 173 others
Phase 3
284 of 3,597
41 open now
Registered
2,678th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 721st largest by enrollment of the 3,024 interventional ones that give a count, is one of 174 that started in 2021, is one of 284 in phase 3, and was the 2,678th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.

03

Conditions studied

  • Prostate Cancer
  • Prostate Cancer Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male with original diagnosis of adenocarcinoma of the prostate with prior definitive therapy
  • Suspicion of recurrence or persistence

    • after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir (ASTRO-Phoenix)
    • after prostatectomy, PSA > 0.2 ng/mL on 2 or more determinations (recurrence), or failure of PSA to fall to undetectable levels post-prostatectomy (persistence) (American Urological Association)
  • For patients who previously had radical prostatectomy, salvage radiotherapy is one likely treatment plan; for patients who initially underwent radiotherapy (including brachytherapy), confirmation of low volume disease is needed to define (local) treatment.
  • of 6 months or more as judged by the investigator
  • Willing and able to undergo all study procedures
  • in writing

Exclusion criteria

Exclusion Criteria:

  • Age: less than18 years
  • to any of the ingredients of [18F]PSMA-1007
  • Close affiliation with the site
  • At the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial
  • Having been previously enrolled in this clinical trial
  • Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial
  • Being clinically unstable or requiring emergency treatment
  • Patients who are unwilling to consider a if clinically recommended
  • Patients who are unable to undergo a PET/CT scan
  • Patients for whom systemic therapy is the most likely course regardless of PET findings.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    [18F]PSMA-1007

    single intravenous administration of \[18F\]PSMA-1007 for Positron Emission Tomography (PET) scan

    Drug: [18F]PSMA-1007

Interventions

06

What researchers measure

Primary outcomes

  1. Region-level positive predictive value (PPV) of [18F]PSMA-1007 using a combined standard of truth (SOT)

    Time frame: Within 6 months after PET/CT

  2. Patient-level correct detection rate of [18F]PSMA-1007

    Time frame: Within 6 months after PET/CT

07

Study locations

6 sites
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Excel Diagnostics and Nuclear Oncology Center
    Houston, Texas 77042, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • RUMC
    Nijmegen, Netherlands
  • Inselspital, Universitätsspital
    Bern, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jun 2023, 21 months.

Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 21 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 8, 2021
StartActual
Aug 27, 2021
Primary completionActual
Jun 23, 2023
CompletionActual
May 5, 2025
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04742361
Lead sponsor
ABX advanced biochemical compounds GmbH
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Aug 27, 2021
Primary completion
Jun 23, 2023
Completion
May 5, 2025
Last update
Jul 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PSMA-1007

Start the discussion